A Randomized Phase II Study of INC280 (capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
| Protocol No. | S1900G | Scope | National |
|---|---|---|---|
| Principal Investigator | Rohan Maniar | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase II |
